Welcome to
Breckenridge Pharmaceutical, Inc.

 TOWA PHARMACEUTICAL CO.,LTD.

Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa Pharmaceutical (Osaka, Japan), markets and distributes quality, cost-effective generic pharmaceuticals in the United States.  Our products are developed in our affiliated research and development centers, as well as through strategic partnerships nationwide and around the world. With our dedication to customer service, on-time delivery, reliable supply and quality manufacturing, we improve the health and lives of the patients we and our customers serve.

 

 

Latest News

Everolimus 10mg (Afinitor) Launched

Oct 01,2021

Breckenridge Pharmaceutical, Inc. announces today that it has launched the 10mg strength of Everolimus Tablets (generic for Afinitor®).  The U.S. Food and Drug Administration previously granted final approval of this Abbreviated New Drug Application.  This product was developed in collaboration with Natco Pharma Limited. According to industry sales data, the 10mg strength of Afinitor generated annual sales of $392 million during the twelve months ending July 2021.  Breckenridge previously launched its Everolimus tablets in 2.5mg, 5mg and 7.5mg strengths during the second quarter of 2021.

 

About Breckenridge:

Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa Pharmaceutical (Osaka, Japan), markets and distributes quality, cost-effective generic pharmaceuticals in the United States.  Our products are developed in our affiliated research and development centers, as well as through strategic partnerships nationwide and around the world. With our dedication to customer service, on-time delivery, reliable supply and quality manufacturing, we improve the health and lives of the patients we and our customers serve.

www.bpirx.com

 

About Natco:

Natco Pharma Limited is a global generic pharmaceutical research, development, manufacturing and marketing company. The company was established in 1981 in India. Natco supplies pharmaceutical products to over 50 countries across the globe, including the United States. Natco focuses on the development and manufacturing of oncology and other specialty pharmaceuticals.

www.natcopharma.co.in

 

 

For further information, please contact:

Breckenridge Pharmaceutical, Inc.

Robert Gasparino, Associate Vice President – Business Development

Tel: 860-828-8140

E-mail: rgasparino@bpirx.com

Read More >>

ANDA Approval for Teriflunomide Tablets

Sep 29,2021

Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted approval of its Abbreviated New Drug Application for Teriflunomide Tablets (generic for Aubagio®). This product was developed in collaboration with PharmaZell GmbH, Germany. Breckenridge received final approval for the 7mg and 14mg strengths.   Sanofi Aventis LLC and Breckenridge have entered into a Settlement Agreement that permits Breckenridge to launch its generic teriflunomide product on March 12, 2023. According to industry sales data, Aubagio generated annual sales of approximately $1.9 billion during the twelve months ending July 2021. 

 

About Breckenridge:

Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa Pharmaceutical (Osaka, Japan), markets and distributes quality, cost-effective generic pharmaceuticals in the United States.  Our products are developed in our affiliated research and development centers, as well as through strategic partnerships nationwide and around the world. With our dedication to customer service, on-time delivery, reliable supply and quality manufacturing, we improve the health and lives of the patients we and our customers serve.

www.bpirx.com

 

About Pharmazell:

The PharmaZell Group supplies the pharmaceutical industry with Active Pharmaceutical Ingredients and natural source materials. The Group operates production facilities in Germany, Italy and India and offers a focused portfolio of small molecule APIs combined with Custom Development and Manufacturing Services for the pharmaceutical industry worldwide.

www.pharmazell-group.com

 

For further information, please contact:

Breckenridge Pharmaceutical, Inc.

Robert Gasparino, Associate Vice President – Business Development

Tel: 860-828-8140

E-mail: rgasparino@bpirx.com

Read More >>

Norepinephrine Bitartrate Injection, USP launch

Aug 20,2021

Breckenridge Pharmaceutical, Inc. Announces Launch of Norepinephrine Bitartrate Injection, USP (generic for Levophed®)

 

Berlin, Connecticut, August 20, 2021

 

Breckenridge Pharmaceutical, Inc. announces today that it has launched Norepinephrine Bitartrate Injection, USP (generic for Levophed®), manufactured by Rafarm S.A.  Breckenridge will market the product in its own label and offer 4 mg/4 mL (1 mg /mL) strength in cartons of 10 vials.  According to industry sales data, Levophed and its generics had annual sales of $65 million during the twelve months ending June 2021. The U.S. Food and Drug Administration previously granted final approval of this product’s Abbreviated New Drug Application. 

 

 

About Breckenridge:

Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical (Osaka, Japan), partners with manufacturers nationwide and around the world to bring quality, cost-effective generic pharmaceuticals to U.S. patients.  With our dedication to customer service, on-time delivery, reliable supply and quality manufacturing, we improve the health and quality of life of the patients we and our customers serve.

www.bpirx.com

Read More >>

Product Search

All brand names are registered trademarks of their respective owner(s).